tirzepatide day 3 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for Week 3 done. 4kg down.

A new study from the NYU Grossman School of Medicine, led by Lucas Mavromatis, suggests that #GLP1 receptor agonists - like #Ozempic #Semaglutide and #Zepbound #Tirzepatide - may do more than manage #diabetes and #weight: they could also help reduce the risk of 14 #obesity-related #cancers, especially in women

3,015.00 Will Ship in One Business Day (3) Highest dose of glutathione on the market and highly absorbable 2,200.00 In Stock

However, room-temperature injection remains the preferred method for patient comfort and optimal absorption consistency

& Ray, K

If you experience any suspected side effects from medications, report them via the MHRA Yellow Card scheme